SS Innovations International (NASDAQ: SSII) has reported significant growth in the utilization and global reach of its SSi Mantra surgical robotic system, with cumulative procedures reaching 14,103 as of September 8, 2026, a 79% increase from 7,885 at the end of 2025. The installed base of systems grew 42% to 238 units, up from 168, according to the company's recent update. This expansion matters because it demonstrates accelerating adoption of a cost-effective robotic surgery platform in markets where advanced surgical technology has historically been limited, potentially reshaping global access to minimally invasive procedures.
The SSi Mantra is now installed in 12 countries, and approximately 1,500 physicians have been trained on the system, which has been used for more than 170 types of surgical procedures. Recent international milestones include the launch of robotic cardiac surgery in Colombia, the first installation of an SSi Mantra in Sri Lanka, and the first telesurgery within the Philippines. These developments are important because they highlight the system's versatility and its ability to facilitate complex operations, including cardiac surgery, in diverse healthcare settings.
Additionally, SS Innovations reported 258 cumulative pediatric robotic surgeries and 188 robotic telesurgeries as of August 31, including a telesurgery performed over a distance of more than 13,600 miles between Colombia and India. In August, five SSi Mantra systems were used to complete 50 robotic general surgery procedures in a single day in India. Such achievements underscore the potential of telesurgery to bridge geographical gaps in surgical expertise, which could be particularly impactful for underserved regions.
Looking ahead, the company expects the U.S. Food and Drug Administration to complete its review of the SSi Mantra 510(k) premarket notification by the end of the first quarter of 2027 and believes European Union CE marking certification can be obtained by year-end 2026. These regulatory milestones are critical because they would open access to two of the world's largest medical device markets, significantly expanding the company's addressable market and competitive position.
SS Innovations International, Inc. develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. The company's product range includes its proprietary SSi Mantra surgical robotic system and its comprehensive suite of SSi Mudra surgical instruments, which support a variety of surgical robotic procedures including cardiac surgery. An American company headquartered in India, SS Innovations plans to expand the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions.
For more details, the full report is available at https://ibn.fm/DJILj. The latest news and updates relating to SSII are available in the company's newsroom at https://ibn.fm/SSII. Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer.
